ATXN2 and amyotrophic lateral sclerosis: Finally, lowering of ataxin-2, which has been genetically linked to ALS (intermediate expansions associated with ALS; ref. 15) in a clinical trial of patients with sporadic ALS did not lower neurofilament levels nor improve clinical outcomes.